NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $1.07 +0.07 (+7.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.07 +0.00 (+0.28%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lucid Diagnostics Stock (NASDAQ:LUCD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$1.03▼$1.1150-Day Range$0.95▼$1.4152-Week Range$0.90▼$1.70Volume1.55 million shsAverage Volume913,385 shsMarket Capitalization$217.28 millionP/E RatioN/ADividend YieldN/APrice Target$4.13Consensus RatingModerate Buy Company Overview Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients. Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States. The company’s test is billed under existing procedural codes, and Lucid engages with payers to secure coverage and reimbursement. In addition to its core oral cancer test, the company is developing complementary assays and workflow enhancements aimed at broadening its diagnostic portfolio and supporting earlier intervention in head and neck malignancies. Headquartered in the Pacific Northwest, Lucid Diagnostics began trading on the NASDAQ under the ticker LUCD in mid-2021 following a strategic reorganization and capital raise. The senior management team comprises professionals with backgrounds in in-vitro diagnostics, clinical laboratory operations and life-science commercialization. Looking ahead, Lucid is focused on expanding its sales footprint, advancing payer relationships and exploring international distribution agreements to extend access to its non-invasive oral cancer detection platform.AI Generated. May Contain Errors. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 87% of companies evaluated by MarketBeat, and ranked 59th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLucid Diagnostics has a consensus price target of $4.13, representing about 285.5% upside from its current price of $1.07.Amount of Analyst CoverageLucid Diagnostics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.22) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 6.19.Change versus previous monthShort interest in Lucid Diagnostics has recently decreased by 4.57%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentLucid Diagnostics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat Follows3 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $245,000.00 in company stock, which represents 0.1128% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $245,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders6.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUCD Stock News HeadlinesDennis Matheis Buys 245,000 Shares of Lucid Diagnostics (NASDAQ:LUCD) StockMay 22 at 8:00 AM | insidertrades.comCanaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)May 16, 2026 | theglobeandmail.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...May 15, 2026 | finance.yahoo.comPAVmed Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | prnewswire.comLucid Diagnostics Earnings Call Balances Progress, PressureMay 14, 2026 | tipranks.comLucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $1.09 at the start of the year. Since then, LUCD shares have decreased by 1.8% and is now trading at $1.07. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The firm had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.38 million. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Tuesday, October 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Lucid Diagnostics' major shareholders? Lucid Diagnostics' top institutional shareholders include Sunbelt Securities Inc. (0.44%), Renaissance Technologies LLC (0.26%), XML Financial LLC (0.13%) and Bank of America Corp DE (0.04%). Insiders that own company stock include Dennis Matheis and Stanley Lapidus. View institutional ownership trends. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings5/14/2026Today5/22/2026AGM 20266/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LUCD's financial health is in the Yellow zone, according to TradeSmith. LUCD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year Founded1991Price Target and Rating Average Price Target for Lucid Diagnostics$4.13 High Price Target$9.00 Low Price Target$2.00 Potential Upside/Downside+285.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.01 million Net Margins-876.72% Pretax Margin-876.72% Return on EquityN/A Return on Assets-116.26% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.05 Sales & Book Value Annual Sales$4.71 million Price / Sales46.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-35.67Miscellaneous Outstanding Shares203,070,000Free Float189,258,000Market Cap$217.28 million OptionableNo Data Beta1.10 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:LUCD) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
